Biocon Secures U.S. FDA Approval for Pebrilzo, Its Fifth Oncology Biosimilar, with U.S. Launch Expected in 2028
Biocon Limited has received U.S. Food and Drug Administration (FDA) approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Roche’s Perjeta® (pertuzumab), marking a significant milestone in the company’s oncology business and its efforts to expand access to affordable cancer treatments.










